Strategic Expansion of Perspectum Group’s Quantitative Imaging Platform in Latin America

Perspectum Group PLC, the Oxford‑based biotechnology firm that develops digital imaging solutions for metabolic disease and cancer, announced a new strategic partnership with Avant Santé on 5 January 2026. The collaboration is designed to strengthen quantitative imaging capabilities for metabolic and liver research across Mexico and the broader Latin American region.

Partnership Overview

  • Partner: Avant Santé, a patient‑centric contract research organization headquartered in Monterrey, Mexico.
  • Focus: Support clinical research programs that evaluate metabolic health and liver disease for sponsors operating in Mexico and Latin America.
  • Geographic Reach: Mexico is highlighted as a pivotal site for clinical trials in metabolic and liver disease because of its large population burden and an increasing emphasis on evidence that reflects real‑world diversity.

Regulatory Context

Mexico’s health regulator, COFEPRIS, has been modernizing its processes. The DIGIPRiS platform is streamlining digital submissions of research protocols, which aligns with Perspectum’s emphasis on advanced, data‑centric imaging solutions. The partnership therefore benefits from a regulatory environment that favors digital innovation and faster protocol approvals.

Technical Synergies

Perspectum’s imaging platform delivers high‑throughput, quantitative assessment of metabolic organs and liver tissue. By integrating Avant Santé’s patient‑centric clinical trial expertise, sponsors will gain:

  1. Enhanced Data Capture – Advanced imaging metrics combined with robust clinical endpoints.
  2. Increased Patient Diversity – Access to a broader patient population representative of Latin American demographics.
  3. Accelerated Trial Timelines – Leveraging COFEPRIS’s DIGIPRiS streamlined approvals to reduce administrative delays.

Strategic Implications

The alliance positions Perspectum to:

  • Expand its global footprint in a region that is becoming a hotspot for metabolic disease research.
  • Deepen relationships with key regulatory bodies by demonstrating compliance with Mexico’s digital submission standards.
  • Offer sponsors a differentiated platform that couples quantitative imaging with a patient‑centric trial infrastructure, potentially accelerating drug development timelines.

Outlook

As metabolic and liver disorders continue to rise worldwide, the demand for precise, scalable imaging solutions grows. Perspectum’s collaboration with Avant Santé signals a proactive step toward meeting that demand in a geographically diverse and regulatory‑friendly market. The partnership is expected to drive both clinical innovation and commercial growth for Perspectum Group in the coming years.